Repository logo

Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease.

Accepted version

Change log


Peng, Jiajie 
Liao, Zhixiang 
Locascio, Joseph J 
Corvol, Jean-Christophe 


A key driver of patients' well-being and clinical trials for Parkinson's disease (PD) is the course that the disease takes over time (progression and prognosis). To assess how genetic variation influences the progression of PD over time to dementia, a major determinant for quality of life, we performed a longitudinal genome-wide survival study of 11.2 million variants in 3,821 patients with PD over 31,053 visits. We discover RIMS2 as a progression locus and confirm this in a replicate population (hazard ratio (HR) = 4.77, P = 2.78 × 10-11), identify suggestive evidence for TMEM108 (HR = 2.86, P = 2.09 × 10-8) and WWOX (HR = 2.12, P = 2.37 × 10-8) as progression loci, and confirm associations for GBA (HR = 1.93, P = 0.0002) and APOE (HR = 1.48, P = 0.001). Polygenic progression scores exhibit a substantial aggregate association with dementia risk, while polygenic susceptibility scores are not predictive. This study identifies a novel synaptic locus and polygenic score for cognitive disease progression in PD and proposes diverging genetic architectures of progression and susceptibility.



Apolipoprotein E4, Cognition, Cognition Disorders, Disease Progression, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Glucosylceramidase, Humans, Longitudinal Studies, Multifactorial Inheritance, Mutation, Parkinson Disease, Proportional Hazards Models, Risk Factors, Survival Analysis, Synapses

Journal Title

Nat Genet

Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC
Wellcome Trust (203151/Z/16/Z)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Medical Research Council (MR/R007446/1)
Medical Research Council (MC_PC_17230)